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Objective: We compared pooled estimates of event rates for amputations, conduit failures, reinfections, early mortalities,
and late mortalities in patients with aortic graft infection who were treated by extra-anatomic bypass, rifampicin-bonded
prostheses, cryopreserved allografts, or autogenous veins.
Methods: A systematic review was conducted of English language reports in MEDLINE back to 1985 and a meta-analysis
was performed on the results. Studies were selected on the basis of medical subject headings aortic, graft, and infection,
and also by a standardized and independent quality rating. Inclusion and exclusion criteria were met by 37 clinical studies.
Pooled estimates of mean event rates for amputations, conduit failures, reinfections, early (<30 day) mortalities, and late
(>30 days) mortalities were determined for each treatment modality. Tests of heterogeneity and sensitivity analyses were
performed.
Results: Fixed effect analyses, derived after tests of heterogeneity, yielded overall pooled estimates of mean event rates for
all outcomes combined of 0.16 for extra-anatomic bypass, 0.07 for rifampicin-bonded prostheses, 0.09 for cryopreserved
allografts, and 0.10 for autogenous vein; a lower value signifies fewer overall events associated with the treatment
modality. Overall, the robustness of our meta-analysis was demonstrated by the reasonable heterogeneity of pooled data
from individual studies (Q statistic<25; P>.1 for all treatment outcomes across all modalities) and the limited variability
of outcomes after sensitivity analyses.
Conclusion: Although limited by the design of individual published studies whose data were pooled together in this
meta-analysis, our results lead to questions concerning whether extra-anatomic bypass should remain the gold standard
for treatment of aortic graft infection. (J Vasc Surg 2006;44:38-45.)The incidence of prosthetic aortic graft infections over
the past three decades has been reported at 0.6% to 3%.1,2
The prognosis depends on various factors such as the site of
the graft and the underlying condition of the patient.2 The
most widely accepted standard treatment for infected aortic
grafts includes complete graft excision and local débride-
ment, followed by extra-anatomic bypass revascularization
through a noninfected field.3 Drawbacks to extra-anatomic
bypass include low patency, lengthy procedure, relatively
high amputation rate, significant risk of rupture of the
aortic suture line, and difficulty of extra-anatomic routing
in the inguinal region.4,5 Consequently, to minimize these
problems while delivering other benefits, in situ reconstruc-
tion has been attempted in appropriately selected patients
using various conduits, including autogenous veins,6 cryo-
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38preserved allografts,7 and synthetic prostheses that are ei-
ther rifampicin-bonded or silver-coated.8,9
Despite the promising clinical results reported for in
situ reconstruction, there has not been a systematic
review and meta-analysis comparing the clinical out-
comes associated with the four treatment modalities for
aortic graft infection—extra-anatomic bypass, rifampi-
cin-bonded prostheses, cryopreserved allografts, and au-
togenous veins. A meta-analysis is a method of enabling
the statistical analysis of a large collection of results from
individual studies for the purpose of integrating the
findings and permitting comparisons to be made, which
differs from a literature review alone as a new result is
obtained. This method makes it possible to compare the
outcomes data reported from studies involving the vari-
ous treatment modalities for aortic graft infection.10
Through tests of heterogeneity and appropriate sensi-
tivity analyses, valid comparisons between pooled data from
multiple studies may be performed within a meta-
analysis.10 Silver-coated grafts, although a recent promising
entry into the arsenal of available treatment modalities for
aortic graft infection,9 are not included in such a meta-
analysis given that only one clinical study, from seven
centers and involving 27 patients to date, documents the
use of this specific treatment modality.
The purpose of this systematic review and meta-analysis
was to compare statistically the pooled estimates of mean
event rates for amputation, conduit failure, reinfection,
early mortality, and late mortality from clinical studies
involving extra-anatomic bypass, rifampicin-bonded pros-
likely
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treatment modalities for aortic graft infection.
METHODS
Search strategy. A literature search confined to stud-
ies published in the English language was done using
MEDLINE from January 1985 to August 2005. Medical
subject headings (MeSH) for the search were aortic, graft,
and infection, and the following keywords were also used:
rifampin- or rifampicin-coated polyester grafts, Dacron,
PTFE, autogenous vein, cryo-preserved vein, and extra-
anatomic bypass. References from identified studies were
also reviewed to ensure that all pertinent published papers
had been identified. Inclusion/exclusion criteria (Table I)
were fulfilled by 37 publications; six studies were excluded
because they were case studies or clinical studies not pub-
lished in the English language. Nearly all of the studies used
in this meta-analysis were retrospective and observational;
as expected, none were randomized controlled trials. More
details regarding the studies reviewed and the analyses
performed are detailed in Appendices A–K (online).
Outcomes measured. Outcomes were quantified as
pooled estimates for each treatment modality of mean
event rates for amputations, conduit failures (thrombosis,
stenosis, or both), reinfections, early mortalities, and late
mortalities. Given the nature of data reported in most of the
individual studies available for use in this meta-analysis,
event rates are the most reasonable means of statistically
comparing the outcomes across treatment modalities. Few
studies reported the outcomes data in a standardized way
(eg, Kaplan-Meier curves) that would enable unbiased and
accurate comparisons between studies by means other than
event rates. However, use of event rates does make any
outcomes data especially sensitive to variables such as
length of follow-up; consequently, this was one of the
sensitivity analyses performed in this meta-analysis. Early
mortality was defined as death 30 days postoperatively
Table I. Inclusion and exclusion criteria used to determin
Inclusion criteria
● Clinical studies with study designs that include retrospective pa
registries, prospective multicenter data surveys, and prospective
● Clinical studies involving patients treated for prosthetic aortic g
● Clinical studies involving the use of extra-anatomic bypass, anti
veins.
Exclusion criteria
● Case studies.
● Studies that exclusively involve patients within a narrow age ran
patients.*
● Clinical studies not published in the English language.
● Clinical studies that document the exclusive or disproportionat
infection.*
● Clinical studies with poor reporting of patient characteristics an
*Studies with exclusively young or old patients (small age range), or e
methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, etc) areand late mortality as death 30 days postoperatively.Selection. Two reviewers, both blinded to the authors
and results of the selected publications, used a standardized
scoring system10 to rate the clinical and methodologic
quality of each study. Studies that did not rate above a
threshold quality score (eg, 18/28) were excluded from
the meta-analysis; all studies that met the inclusion and
exclusion criteria were found to have quality scores above
the threshold. Quality scores assigned to studies were not
used to weight the results from individual studies.11
Data extraction and analysis. Two reviewers inde-
pendently extracted the data from each selected publica-
tion. Inter-rater reliability was high. Both men and women,
with a mean age of approximately 60 years (range, 25 to 93
years), were part of the patient pool. Although the reasons
for the initial operation varied, with occlusive disease being
the predominant indication in 27% to 94% of patients
involved in individual studies, variability was noted in pa-
tient characteristics such as comorbidities and etiology of
the aortic graft infection.
Data were analyzed using dedicated meta-analysis sta-
tistical software (BioStat Inc, Morristown, NJ), from which
pooled estimates of mean event rates with 95% confidence
limits were calculated. The results of fixed and random
effect analyses were generated. Methods of fixed effect
meta-analysis are based on the mathematic assumption that
a single common (or “fixed”) effect underlies every individ-
ual study in the meta-analysis. A random effects analysis
makes the assumption that individual studies are estimating
different treatment effects. If fixed effect and random effect
meta-analyses give identical results, then it is unlikely that
there is important statistical heterogeneity. Study weights
were calculated and were the basis for excluding specific
study data as required after tests of heterogeneity.
Tests of heterogeneity. The Q statistic, a statistical
measure of homogeneity between studies,12 was deter-
mined; a large value of Q indicates significant heterogeneity
between studies. The significance level for the Q statistic
ction of clinical studies from the MEDLINE database
chart reviews, single-arm nonrandomized clinical trials, clinical
andomized studies.
fection, mycotic aneurysm, or both.
-bonded prostheses, cryopreserved allografts, or autogenous
15 years difference), whether exclusively young or old
lvement of highly virulent microorganisms in the aortic graft
vant outcomes data.10,11
ve or disproportionate presence of highly virulent microorganisms (eg,
to bias the pooled event rates for that specific treatment modality.e sele
tient
nonr
raft in
biotic
ge (
e invo
d rele
xclusiwas set at P  .1, as recommended.12 Where an unreason-
nce o
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within treatment modalities were performed to identify
causes of unreasonable heterogeneity. Studies identified as
the source of unreasonable heterogeneity were excluded,
and pooled estimates of mean event rates were regenerated.
Sensitivity analyses. The sensitivity analyses reflect
the characteristics of the patient pool for the multicenter
clinical study involving silver-coated prostheses.9 The fol-
lowing variables were used to exclude results from specific
studies to determine the subsequent effect on the overall
pooled estimates of mean event rates: (1) partial excisions
29% of all excisions performed, (2) 41% of cases per-
formed emergently, (3) patients with aortoenteric fistulas
accounted for 44% of treated population, (4) mean
length of follow-up 16.5 months, (5) sepsis reported in
44% of treated population (sepsis was categorized as
reported clinical signs of fever, leukocytosis, bacteremia,
and positive blood cultures or where sepsis was specifically
identified), and (6) aortic graft indication for occlusive
disease in 70% of the treated population.
Publication bias. A funnel plot was constructed for
C
A
Fig. Funnel plots to assess publication bias in analyses co
prostheses (B), cryo-preserved allografts (C), and autoge
the horizontal axis and the measure of its precision (eg, 1/
modality are approximately symmetrical, indicating abseeach treatment modality to estimate the presence of majorpublication bias (Fig). The y-axis represents the precision
(reciprocal of the standard error) and the x-axis represents
the effect size. The most precise estimates (for example,
those from the largest studies), therefore, are at the top of
the funnel, and those from less precise or smaller studies are
at the base of the funnel plot.
RESULTS
The mean number of patients across all studies was 33
(range, 5 to 134). The mean total number of patients per
treatment modality was 38 (range, 5 to 134) for extra-
anatomic bypass, 19 (range, 11 to 27) for rifampicin-
bonded prostheses, 39 (range, 6 to 90) for cryopreserved
allografts, and 24 (range, 7 to 58) for autogenous veins.
The mean number of studies per treatment modality was 11
(range, 5 to 16). The total number of studies was 12 for
extra-anatomic bypass, 5 for rifampicin-bonded prostheses,
16 for cryo-preserved allografts, and 9 for autogenous
veins.
Table II provides the pooled estimates of mean event
rates per outcome for each treatment modality before and
B
D
ing extra-anatomic bypass grafts (A), rifampicin-bonded
veins (D). The treatment measure (eg, event rate) is on
rr) is on the vertical axis. Funnel plots for each treatment
f major publication bias.ncern
nous
Std Eafter tests of heterogeneity. The rank order of pooled
preser
enou
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that amputations, conduit failures, and early mortalities
were lowest for rifampicin-bonded prostheses. However,
reinfection was worst for rifampicin-bonded prostheses (af-
ter tests for heterogeneity) and lowest for autogenous
veins, followed closely by cryopreserved allografts. Late
mortality was equally lowest for autogenous veins and
cryopreserved allografts. Despite the shifts in rank order
made by extra-anatomic bypass after tests of heterogeneity,
the rank order still favored other in situ reconstruction
options across all outcomes combined (P  .05).
Table III presents the results of sensitivity analyses.
There was no change in pooled estimates of mean event
rates among all outcomes for any treatment modality when
partial excisions comprised29% of all excisions. However,
when 41% of treated cases were emergent, changes oc-
curred in various outcomes for both extra-anatomic bypass
and cryopreserved allograft. When 44% of treated pa-
tients had aortoenteric fistulas, there were changes in mean
event rates for extra-anatomic bypass alone. When the
mean follow-up duration was 16.5 months, changes oc-
curred in mean event rates across nearly all outcomes for all
treatment modalities. When sepsis was apparent in44% of
treated patients, changes were noted in mean event rates for
extra-anatomic bypass and cryo-preserved allografts. When
the initial procedure indication for aortic graft infection was
for occlusive disease in70% of treated patients, there were
changes in mean event rates for a number of outcomes
across all treatment modalities.
The figure shows funnel plots for studies of each mo-
dality. Each plot suggests the absence of major publication
bias, given that each plot is approximately symmetrical on
visual observation and by determination of the intercept
Table II. Pooled estimates of mean event rates for the ou
heterogeneity using fixed effect analyses
Outcomes
Extra-anatomic bypass
(n  459)
Rifam
Before tests of heterogeneity
Amputation 0.12†‡
Conduit failure 0.20‡
Reinfection 0.07§
Early mortality 0.15†
Late mortality 0.33
All outcomes combined 0.17†‡§
After tests of heterogeneity
Amputation 0.08†
Conduit failure 0.25‡
Reinfection 0.06§
Early mortality 0.18†
Late mortality 0.24
All outcomes combined 0.16†‡§
*Too few results available for statistical comparison. Mann-Whitney ranks s
†Statistically significant difference between extra-anatomic bypass and rifam
‡Statistically significant difference between extra-anatomic bypass and cryo-
§Statistically significant difference between extra-anatomic bypass and autoga.13DISCUSSION
Systematic reviews and meta-analyses can provide con-
vincing and reliable evidence relevant to many aspects of
medicine and health care.14 The review and analysis pre-
sented here involves published, high-quality clinical studies
that concern the treatment of infected grafts in humans.
Therefore, there was no reliance on preclinical studies,
which often report results that cannot be directly extrapo-
lated to humans or otherwise have been based on poor
study designs.15-17 Our results have been derived from
individual studies that have involved patients aged 25 to 93
years (although most individual studies reported the mean
age of their patient population to be in the sixth decade)
who primarily had low virulence aortic graft infections.
The results summarized in Table II, after tests of
heterogeneity, suggest that rifampicin-bonded prostheses
are associated with fewer amputations, conduit failures, and
early mortalities than other treatment modalities for aortic
graft infection. Surprisingly, however, reinfection was
worst for rifampicin-bonded prostheses and lowest for au-
togenous veins, followed closely by cryopreserved allo-
grafts. Autogenous veins had the lowest pooled estimates of
event rates for reinfection, followed closely by cryopre-
served allografts. Late mortality was equally lowest for
autogenous veins and cryopreserved allografts. When all
outcomes combined are considered, the rank order favored
any in situ reconstruction options over extra-anatomic by-
pass.
Our results lead to the question of whether extra-
anatomic bypass should remain the gold standard for treat-
ment of infected vascular grafts, given the rank order of
pooled estimates of event rates where this modality trails in
situ reconstruction options across many outcomes. Reach-
es derived from all studies before and after tests of
-bonded prosthetic
 96)
Cryo-preserved allograft
(n  616)
Autogenous vein
(n  219)
0 0.03 0.08
0.02* 0.09 0.17
0.07 0.03 0.01
0.07 0.14 0.10
0.16 0.14 0.14
0.07 0.09 0.10
0 0.03 0.08
0.02* 0.09 0.17
0.07 0.03 0.01
0.07 0.14 0.10
0.16 0.14 0.14
0.07 0.09 0.10
atistical test used for group comparisons.
bonded prostheses (P  .05).
ved allografts (P .05).
s veins (P  .05).tcom
picin
(n
um st
picin-ing such a conclusion based on the results of this meta-
comp
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inclusion/exclusion criteria used to select individual studies
and the data extracted from them for this meta-analysis may
not adequately represent the broad range of clinical mani-
festations of graft infections nor enable specific patient
subgroups to be identified who may most benefit from a
specific treatment modality like extra-anatomic bypass.
Nonetheless, extra-anatomic bypass does have disad-
vantages, for example, a lengthy time of intervention.
Moreover, aortic stump suture is not always possible with
this technique when the stump is short, and the risk for
thrombosis ascending towards the renal arteries is com-
pounded by the risk of aortic stump blowout.9
A potential benefit of extra-anatomical reconstruction
is that the revascularization is away from the site of infec-
tion, and therefore, reinfection might be expected to be
minimal. This has not been borne out in the literature,
however, with reinfection rates of 27% being reported,18
Table III. Changes in pooled estimates of mean event rat
analyses
Outcome Extra-anatomic bypass
Rifam
pr
Sensitivity analysis—partial excisions 29% of all excisions perform
Amputation 0.12 0
Conduit failure 0.20 0
Reinfection 0.07 0
Early mortality 0.15 0
Late mortality 0.33 0
Sensitivity analysis—41% of cases performed emergently
Amputation 0.112 0
Conduit failure 0.211 0
Reinfection 0.062 0
Early mortality 0.142 0
Late mortality 0.361 0
Sensitivity analysis—patients with aortoenteric fistulas 44% of tre
Amputation 0.12 0
Conduit failure 0.20 0
Reinfection 0.081 0
Early mortality 0.142 0
Late mortality 0.361 0
Sensitivity analysis—mean length of follow-up 16.5 months
Amputation 0.102 0
Conduit failure 0.192 0
Reinfection 0.062 0
Early mortality 0.161 0
Late mortality 0.132 0
Sensitivity analysis—sepsis reported in 44% of treated population
Amputation 0.112 0
Conduit failure 0.20 0
Reinfection 0.062 0
Early mortality 0.142 0
Late mortality 0.162 0
Sensitivity analysis—aortic graft indication for occlusive disease in
Amputation 0.112 0
Conduit failure 0.192 0
Reinfection 0.062 0
Early mortality 0.15 0
Late mortality 0.33 0
Arrows indicate whether an event rate has increased (1) or decreased (2)
baseline, no symbol is shown.although this percentage refers to a large proportion ofaortoenteric fistulas and quite a large proportion of emer-
gent operations within the patient pool. A further compli-
cation with this particular technique is the likelihood of
compromised blood supply to the pelvis and colon after the
procedure due to the inability to effectively revascularize
the internal iliac arteries and inferior mesenteric artery.19
Autogenous vein for in situ reconstruction of in-
fected grafts is claimed to be the most effective means of
avoiding reinfection.20,21 Our analysis supports this
claim, as the rank order of pooled estimates show that the
least number of reinfections occur with autogenous vein
reconstruction, followed closely by cryopreserved allo-
grafts. There are, however, disadvantages associated with
the use of autogenous vein, including lengthier operative
time, which is an important consideration for fragile
patients and those in life-threatening situations, as well
as contraindication in patients with previous deep vein
thrombosis. A history of femoropopliteal reconstruction
r each comparator treatment after specific sensitivity
bonded
tic Cryopreserved allograft Autogenous vein
0.03 0.08
0.09 0.17
0.04 0.01
0.14 0.10
0.14 0.14
0.03 0.08
0.101 0.17
0.04 0.01
0.14 0.10
0.151 0.14
population
0.03 0.08
0.09 0.17
0.04 0.01
0.14 0.10
0.14 0.14
0.05 0.072
0.101 0.142
0.032 0.01
0.132 0.141
0.14 0.191
0.05 0.08
0.102 0.17
0.032 0.01
0.14 0.10
0.181 0.14
of treated population
0.05 0.08
0.102 0.17
0.03 0.01
0.14 0.10
0.14 0.171
ared with its baseline value. Where there are no differences compared withes fo
picin-
osthe
ed
.02
.07
.07
.16
.02
.07
.07
.16
ated
.02
.07
.07
.16
.02
.081
.081
.152
.02
.07
.07
.16
70%
.012
.091
.081
.211also complicates the excision of the superior femoral vein
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vein reconstruction is considered. Moreover, a recent
study reports additional serious morbidity from vein
harvesting itself and a 35% incidence of fasciotomy in the
limb used for harvesting.22
Although cryopreserved allograft replacement has been
demonstrated to be an effective treatment strategy for
infected aortic prosthetic grafts,23,24 consistent resistance
to reinfection has been held up as the most compelling
attribute of this treatment modality. Indeed, the pooled
estimates of mean event rates for reinfection reported for
cryopreserved allografts across all sensitivity analyses per-
formed, as listed in Table III, demonstrates the robustness
of this attribute. Nonetheless, cryopreserved allografts for
in situ reconstruction have been reported to have a high
complication rate of 23%.18 A further disadvantage of cryo-
preserved allografts is their lack of availability in the re-
quired length, diameter, and shape. Their use in emergent
cases is further complicated by the need to pre-order cryo-
preserved grafts of the required length, diameter, and
shape.
Preclinical studies also suggest that rifampicin-bonded
prostheses may be resistant to reinfection,25,26 but these
have been in vitro rather than in vivo. The use of antibiotic-
bonded prostheses as replacement conduits has, however,
had variable success in clinical practice.8,27-29 Indeed, clin-
ical results suggest that rifampicin-gelatin grafts may be
ineffective against more virulent strains of bacteria30-32
such as methicillin-resistant Staphylococcus aureus (MRSA)
and Escherichia coli and may promote the development of
resistant strains of S epidermidis.
Despite the results of sensitivity analysis, the resistance
or lack of resistance of rifampicin-bonded prostheses to
reinfection may not be fully appreciated, given the combi-
nation of the small number of studies and the small sample
sizes associated with studies of this treatment modality.
Nonetheless, until such drawbacks are fully resolved, our
pooled estimates of mean event rates data and sensitivity
analyses lead us to speculate that rifampicin-bonded pros-
theses may not have the same resistance to reinfection as the
more established treatment options of autogenous veins or
cryopreserved allografts for in situ reconstruction.
In light of the various treatment options available,
perhaps the most difficult aspect of treating aortic graft
infections is selection of the appropriate treatment option
for any given patient.33 For example, in situ autogenous
graft replacement may be most appropriate in younger,
healthier patients who have a greater life expectancy and
thus a higher risk of long-term graft failure, whereas staged
extra-anatomic bypass grafting and graft excision may be
better in older, sicker patients in whom long-term graft
failure may be less important.34
Selection of revascularization technique is also deter-
mined by the aggressiveness of the infecting microorgan-
ism(s).35 The type and virulence of the microorganism(s)
requires careful evaluation, especially in cases of infections
caused by MRSA and gram-negative bacteria.35,36 Al-
though not possible in the current meta-analysis, which wasrestricted to aortic graft infections associated with micro-
organisms of low virulence, future meta-analyses might
consider the affect of these factors if reporting of these
important data in individual studies increases.
Cryopreserved allografts are perhaps more resistant to
infection than prosthetic grafts.20 Unfortunately, they do
degenerate, possibly due to an immune response.37 In
consequence, cryopreserved allografts are less durable than
prosthetic grafts.38 Durability and resistance of autogenous
veins to infection, even in the case of virulent gram-
negative infections, has been documented.21 These con-
duits do not deter MRSA, however, and are unsuitable for
emergent or complicated operations because of the pro-
longed operating time required.38 Overall, these drawbacks
point towards a need for a treatment option that has
demonstrated infection resistance, durability, utility in
emergent or complicated operations, and association with
low mortality and morbidity, which cryopreserved allo-
grafts have not been demonstrated to possess in this litera-
ture review and meta-analysis.
Although not included in this meta-analysis because
results were only available from a single clinical study,9 the
commercial availability in some jurisdictions of silver-
coated prostheses from two manufacturers using different
silver deposition techniques may fulfill the above-
mentioned criteria such as infection resistance, durability,
utility in emergency or complicated operations, and associ-
ation with low mortality and morbidity. Moreover, silver-
coated prostheses have the major benefit of not being
implicated in increasing the resistance to antibiotics, as is
the case with rifampicin-bonded prostheses.31
Our calculation of event rates for the only clinical study
concerning silver-coated prostheses, under conditions of
low virulence infection of aortic grafts, suggests that this
treatment modality may compare favorably with its in situ
comparators and extra-anatomic bypass. However, there is
considerable need for additional high quality data on this
treatment modality to discern whether pooled data from
multiple clinical studies yield consistently low mean event
rates for all outcomes. Moreover, a fuller understanding of
the modes of action of the silver-coated prostheses, espe-
cially their time course, would be helpful in assessing their
utility.
Sensitivity analyses. Inconsistency of the results of
studies in a systematic review and meta-analysis reduces the
confidence of suggested recommendations about treat-
ment. Recognizing that significant differences in patient
and study characteristics may impact the outcomes re-
ported,39 the sensitivity analyses and tests of heterogeneity
that were performed sought to determine the robustness
and validity of the conclusions. The primary reason for the
selection of the sensitivity analyses performed within this
review was because these variables (eg, proportion partial vs
complete excisions performed, proportion emergent vs
elective procedures performed, proportion of patients with
aortoenteric fistula, length of follow-up, proportion of
patients with sepsis, and proportion of patients with occlu-
sive disease) have been reported to affect clinical out-
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against the backdrop of the characteristics that prevailed in
the only published clinical study of silver-coated prosthe-
ses,9 the most recent treatment modality commercially
available for treatment of aortic graft infection.
It should be borne in mind when reviewing the results
of sensitivity analyses that when no effect in pooled event
rates was identified, as seen for many datasets in Table III,
this may be due in part to the fewer number of studies
available for analysis, for example, in the case of rifampicin-
bonded prostheses. As anticipated, there were changes in
pooled estimates of mean event rates with sensitivity anal-
yses. In particular, results show that when the length of
follow-up was limited to 16.5 months an expected de-
crease occurred in the mean event rates for almost every
outcome for the extra-anatomic treatment modality. How-
ever, the decreases in mean event rates were not so large as
to shift the favorable balance heavily towards extra-
anatomic bypass over other treatment modalities.
Study limitations. Some limitations, most related to
potential bias, are associated with this systematic review and
meta-analysis. The selection process for publications and the
manner in which data were pooled from individual studies
may be sources of bias. We took reasonable efforts to limit
such bias by performing heterogeneity assessments, standard-
izing the data extraction process, and executing specific sensi-
tivity analyses to help identify variables that greatly affect the
mean event rate for outcomes. Nearly all analyzed studies were
retrospective and observational, and consequently, problems
with inter-study heterogeneity and selection bias exist.12 De-
spite our reasonable efforts to perform tests of heterogeneity
and appropriate sensitivity analyses, there is a possibility that
some important variables were not considered. For example,
extra-anatomic bypass grafts may have benefits over in situ
reconstruction under specific conditions, but such benefits
may not be captured in the present meta-analysis given the
inclusion/exclusion criteria and the absence of particular sub-
group analyses. Subgroup analyses within each individual
study, which may have considered variables such as age, pre-
senting infections, virulence, comorbidities, and so forth,
would have been beneficial. This was not performed, how-
ever, given the limited data reported for these variables by each
individual study. This is a drawback of the reported studies
themselves and not of this meta-analysis.
The absence of any comparison concerning primary
patency between treatment modalities was due to a combi-
nation of poor reporting of these data and lack of a com-
mon time period for assessing this outcome among studies.
The observational studies used in this meta-analysis were
difficult to analyze and interpret because of the heteroge-
neity of patient populations, the lack of standardized treat-
ment regimens, the lack of standardized indications for
treatment, the lack of predefined end points, and the lack of
specific information on the infecting microorganisms. This
is compounded by the small number of patients available
for analysis for any of the modalities of treatment.
Theoretically, long-term randomized controlled trials
could improve future meta-analyses on this topic. In prac-tice, however, such study designs could not be imple-
mented given the low incidence of vascular graft infection,
the number of therapy modalities available, and the number
of patients required to perform such studies with sufficient
statistical power to determine whether significant differ-
ences do exist. Randomization of patients to the various
treatment modalities would also not find favor with ethics
committees or individual surgeons due to the choice of
reconstruction being so patient-dependent and conse-
quently dependent upon surgeon choice.
Various attempts have been made to launch clinical
registries to collect data on vascular graft infections, but
poor funding and lack of consensus on the data to be
collected and the method of data collection have prevented
this important task from being performed.
As alluded to earlier, our inclusion/exclusion criteria
may have biased the outcome of the meta-analysis. For
example, only clinical studies that reported results in the
English language were considered, with results reported in
non-English language medical journals being excluded. We
believe that publication bias was limited due to the sym-
metrical distribution of Funnel plots shown in Fig 1.
Finally, in some instances it was not entirely clear
whether reported deaths in studies were treatment or non-
treatment related. We did not distinguish between the two,
largely because of a widespread failure of studies to report
mortalities in these distinctive terms. Consequently, the
mortality data may be biased by patient characteristics not
considered in sensitivity analyses (ie, comorbidities).
CONCLUSIONS
The results of our systematic review and meta-analysis
raise the question of whether extra-anatomic bypass should
remain the gold standard for treatment of infected vascular
grafts. In situ replacement may be appropriate in properly
selected patients. As more data on each of the treatment
modalities for infected vascular grafts become available
through clinical registries or trials, there will be a welcome
increase in the pool of data for future systematic reviews and
meta-analyses.
Data were analyzed by an independent organization
(ATLAS Medical Research Inc., St. Lazare, Canada). For
disclosure purposes, this organization has previously ana-
lyzed preclinical and clinical data, and compiled biomedical
and regulatory documentation for medical device, pharma-
ceutical, and biotech companies, as well as university re-
search groups.
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July 200645.e1 O’Connor et alAPPENDIX A (online only). Primary characteristics of c
Author, year
Mean
follow-up
(months) N
Emergent
cases (%)
Aortoenteric
fistulas (%)
Partia
excision
(%)
Extra-anatomic bypass
Yeager 1999 41 60 NS 27 0
Seeger 2000 32 36 NS 0 0
Harris 1989 NS 134 NS NS NS
Sharp 1994 NS 22 NS NS 0*
Schmitt 1990 44 20 NS 45 0
Mingoli 1997 35 18 100 22 0
Lehriert 1993 24 21 NS 0 0
Hart 2005 14 15 NS 70 0
Bandyk 2001 26 34 NS NS NS
Taylor 1988 27 5 NS NS NS
Speziale 2002 31 63 NS 31 NS
Seeger 1999 30 31 NS 19* NS
Rifampicin-bonded prosthesis
Hayes 1999 NS 11 36 36 0
Young 1999 36 25 NS 60* NS
Nasim 1999 NS 11 NS 36 NS
Bandyk 2001 26 22 NS NS NS
Bandyk 2001 17 27 19 NS NS
Cryopreserved allografts
Zhou 2005 8 18 NS NS 0
Desgranges 1998 20 18 17 11* 64
Kitamura 2005 17 6 71 18 50
Kleffer 2001 39 11 73 27 18
Vogt 2002 27 49 61 35* 0*
Chiesa 2002 30 68 17 32 NS
Vogt 1995 19 12 NS NS NS
Nevelsteen 1998 24.5 30 NS 23 NS
Chiesa 1998 15 44 18 30 NS
Teebken 2004 20 42 5* 14 19
Noel 2002 5.3 56 9 7 0
Verhelst 2000 36 90 6 10 27
Leseche 2001 35.4 28 46 25 56
Koskas 1996 NS 83 6 18 0
Kieffier 1993 13.8 43 28 21 0*
Locati 1998 22 18 22 17 0
Autogenous veins
Qagett 1993 22.5 20 NS NS NS
Nevelsteen 1997 16 14 7 21 0
Daenens 2003 41 49 4 0 0
Nevelsteen 1995 17 15 20 13 7
Jicha 1995 44 58 10 41 13
Sicard 1997 24 7 NS NS NS
Bandyk 2001 26 36 NS NS NS
Cardozo 2002 22 12 NS NS 75
Brown 1999 NS 8 NS NS NS
Silver-coated polyester grafts
Batt 2003 17 27 41 44 29
NS, either not specifically stated in the publication or unable to obtain accu
*Possible under- or overestimate of reported data may have occurred. All co
patient is only counted as one event even if it occurred multiple times.
Cryopreserved allografts used in studies included aortic arches, descending t
and tissue between recipient and donor was not attempted in all studies. Res
but these data were not part of the meta-analysis and are for comparison pulinical studies used in this systematic review and meta-analysis.
l
s Sepsis
(%)
Aortic
graft
indication
for
occlusive
disease
(%)
Amputation
(%)
Conduit
failure
(N)
Reinfection
(N)
Early
mortality
(N)
Late
mortality
(N)
NS 58 4 NS 6 8 NS
50* 61 4 13 1 4 16
NS NS 24 24 NS 8 51
NS 30 1 7 1 1 NS
10 65 1 NS 1 3 1
72 50 8 2 6 7 3
NS 81 NS NS 1 2 9
40 27 1 NS 2 5 1
NS NS 3 3 1 7 NS
NS NS 0 NS 1 0 0
NS NS 1 NS 1 19 NS
23 49* 7 NS NS NS NS
18* 36 0 NS 2 2 2
40 56 0 NS 1 2 6
NS NS NS NS 1 0 2
NS NS 0 1 1 1 5
19* 73 0 0 2 2 0
NS NS 2 1 0 3 1
11* 72 1 2 1 4 2
100 NS NS NS 0 3 0
100 NS NS 1 2 2 2
63 NS 0 1 1 3 3
NS NS 3 NS NS 11 17
NS NS NS 0 0 1 2
NS NS 2 NS 2 NS NS
25 NS NS NS NS 6 5
100 NS 1 2 NS 6 4
NS NS 3 5 0 7 7
23 67 1 13 1 16 14
36 87 0 1 0 3 7
NS NS 0 NS NS 12 11
93 72 0 9 2 5 4
67 67 1 1 0 3 1
NS 94* 2 NS 0 1 2
36 43 1 NS 0 2 4
NS 69 1 4 0 4 13
33 60 1 NS 0 1 2
NS 54 10 16 NS 11 5
NS NS 0 2 NS 0 3
NS NS 1 7 1 1 1
NS NS 2 0 0 2 0
NS NS 0 0 0 0 1
44 70 0 0 1 2 2
rate data from the author.
unts are standardized across studies on a per patient basis (ie, an event in a single
Mortality rates comprise both treatment and nontreatment-associated deaths.
horacic aortas, abdominal aorta, and iliac and femoral vessels. Matching by blood
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Fixed effect analyses Point estimate Q value df (Q) P
Amputation
Extra-anatomic bypass 0.16 30.4 11 .001
Rifampicin-bonded prostheses 0.03 0.38 3 .94
Cryopreserved allografts 0.04 9.26 13 .75
Autogenous veins 0.08 5.05 8 .75
Conduit failure
Extra-anatomic bypass 0.28 15.7 6 .016
Rifampicin-bonded prostheses 0.03 0.30 1 .58
Cryopreserved allografts 0.12 12.52 9 .19
Autogenous veins 0.20 9.17 7 .24
Reinfection
Extra-anatomic bypass 0.14 25.6 9 .002
Rifampicin-bonded prostheses 0.10 1.68 4 .79
Cryopreserved allografts 0.04 9.27 11 .60
Autogenous veins 0.03 1.16 7 .99
Early mortality
Extra-anatomic bypass 0.18 32.5 10 .001
Rifampicin-bonded prostheses 0.09 1.98 3 .58
Cryopreserved allografts 0.15 10.95 15 .76
Autogenous veins 0.12 6.74 8 .57
Late mortality
Extra-anatomic bypass 0.36 9.9 3 .019
Rifampicin-bonded prostheses 0.24 0.43 3 .93
Cryopreserved allografts 0.19 21.68 14 .09
Autogenous veins 0.20 9.23 8 .32APPENDIX C (online only). Results from random effect analyses for tests of heterogeneity.
Random effect analyses Point estimate Q value df (Q) P
Amputation
Extra-anatomic bypass 0.13 30.4 11 .001
Rifampicin-bonded prostheses 0.03 0.38 3 .94
Cryopreserved allografts 0.04 9.26 13 .75
Autogenous veins 0.08 5.05 8 .75
Conduit failure
Extra-anatomic bypass 0.24 15.7 6 .016
Rifampicin-bonded prostheses 0.03 0.30 1 .58
Cryopreserved allografts 0.11 12.52 9 .19
Autogenous veins 0.20 9.17 7 .24
Re-infection
Extra-anatomic bypass 0.11 25.6 9 .002
Rifampicin-bonded prostheses 0.10 1.68 4 .79
Cryopreserved allografts 0.04 9.27 11 .60
Autogenous veins 0.03 1.16 7 .99
Early mortality
Extra-anatomic bypass 0.16 32.5 10 .001
Rifampicin-bonded prostheses 0.09 1.98 3 .58
Cryopreserved allografts 0.15 10.95 15 .76
Autogenous veins 0.12 6.74 8 .57
Late mortality
Extra-anatomic bypass 0.26 9.9 3 .019
Rifampicin-bonded prostheses 0.24 0.43 3 .93
Cryopreserved allografts 0.19 21.68 14 .10
Autogenous veins 0.20 9.23 8 .32
Appendix B and C present the results from tests of heterogeneity. The Q statistic did not vary for fixed or random effect meta-analysis across all outcomes for
treatment modalities. This indicates important statistical heterogeneity is unlikely (ie, any differences are due to chance alone). The relatively low Q-values for
all treatment modalities across all outcomes, except for those associated with extra-anatomic bypass, demonstrates reasonable heterogeneity and thus validity
of pooling data from individual studies. The exclusion of three weighted studies involving extra-anatomic bypass (Harris 1989; Lehnert 1993; Mingoli 1997)
removed the statistically significant heterogeneity of pooled data for this treatment modality. After the exclusion of data from these three studies, Q-values for
extra-anatomic bypass were 2.4 for amputation, 0.9 for conduit failure, 5.4 for reinfection, 6.8 for early mortality, and 0.2 for late mortality (P .1 for all
outcomes).
JOURNAL OF VASCULAR SURGERY
July 200645.e3 O’Connor et alAPPENDIX D (online only). Pooled estimates of mean event rates plus ranges for the outcomes of amputation,
conduit failure, reinfection, early mortality, and late mortality derived from all studies before tests of heterogeneity.*
Outcomes
Silver-
Coated
prosthetic
(n  27)†
Extra-anatomic
bypass (n  459)
Rifampicin-
bonded prosthetic
(n  96)
Cryo-preserved
allograft
(n  616)
Autogenous
vein
(n  219)
Before tests of heterogeneity
Amputation 0 0.12 (0-0.44) 0 0.03 (0-0.06) 0.08 (0-0.17)
Conduit failure 0 0.20 (0.09-0.36) 0.02 (0-0.05) 0.09 (0-0.21) 0.17 (0-0.28)
Reinfection 0.04 0.07 (0.02-0.33) 0.07 (0.04-0.09) 0.03 (0-0.18) 0.01 (0-0.03)
Early mortality 0.07 0.15 (0-0.30) 0.07 (0-0.18) 0.14 (0.06-0.50) 0.10 (0-0.19)
Late mortality 0.08 0.33 (0-0.44) 0.16 (0-0.24) 0.14 (0-0.25) 0.14 (0-0.27)
All outcomes combined 0.04 0.17 0.07 0.09 0.1
*Results from fixed effect analyses.
† 9 Results from the only study concerning silver-coated grafts are included in the table, but these data were not part of the meta-analysis and are for comparison
purposes alone.APPENDIX E (online only). Pooled estimates of mean event rates plus ranges for the outcomes of amputation,
conduit failure, reinfection, early mortality, and late mortality derived from all studies after tests of heterogeneity.*
Outcomes
Silver-
Coated
prosthetic
(n  27)†
Extra-anatomic
bypass (n  459)
Rifampicin-
bonded prosthetic
(n  96)
Cryo-preserved
allograft
(n  616)
Autogenous
vein
(n  219)
After tests of heterogeneity
Amputation 0 0.08 (0-0.23) 0 0.03 (0-0.06) 0.08 (0-0.17)
Conduit failure 0 0.25 (0.09-0.36) 0.02 (0-0.05) 0.09 (0-0.21) 0.17 (0-0.28)
Re-infection 0.04 0.06 (0.02-0.13) 0.07 (0.04-0.09) 0.03 (0-0.18) 0.01 (0-0.03)
Early mortality 0.07 0.18 (0-0.30) 0.07 (0-0.18) 0.14 (0.06-0.50) 0.10 (0-0.19)
Late mortality 0.08 0.24 (0-0.44) 0.16 (0-0.24) 0.14 (0-0.25) 0.14 (0-0.27)
All outcomes
combined
0.04 0.16 0.07 0.09 0.1
*Results from fixed effect analyses.
†Results from the only study concerning silver-coated grafts are included in the table,9 but these data were not part of the meta-analysis and are for comparison
purposes alone.APPENDIX F (online only). The rank order of pooled estimates of the event rate for each outcome for all treatment
modalities.
Outcome* Rank order
Before tests of heterogeneity
Amputation Rifampicin-bonded prosthesis  cryo-preserved allograft  autogenous vein  extra-anatomic bypass
Conduit failure Rifampicin-bonded prosthesis  cryo-preserved allograft  autogenous vein  extra-anatomic bypass
Reinfection Autogenous vein  cryo-preserved allograft  rifampicin-bonded prosthesis  extra-anatomic bypass
Early mortality Rifampicin-bonded prosthesis  autogenous vein  cryo-preserved allograft  extra-anatomic bypass
Late mortality Cryopreserved allograft  autogenous vein  rifampicin-bonded prosthesis  extra-anatomic bypass
All outcomes combined Rifampicin-bonded prosthesis  cryo-preserved allograft  autogenous vein  extra-anatomic bypass
After tests of heterogeneity
Amputation Rifampicin-bonded prosthesis  cryo-preserved allograft  extra-anatomic bypass  autogenous vein
Conduit failure Rifampicin-bonded prosthesis  cryo-preserved allograft  autogenous vein  extra-anatomic bypass
Reinfection Autogenous vein  cryo-preserved allograft  extra-anatomic bypass  rifampicin-bonded prosthesis
Early mortality Rifampicin-bonded prosthesis  autogenous vein  cryo-preserved allograft  extra-anatomic bypass
Late mortality Cryopreserved allograft  autogenous vein  rifampicin-bonded prosthesis  extra-anatomic bypass
All outcomes combined Rifampicin-bonded prosthesis  cryo-preserved allograft  autogenous vein  extra-anatomic bypass*Lowest, most favorable, to highest, least favorable
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 1 O’Connor et al 45.e4APPENDIX G (online only). Estimated mean event rates for the outcomes of amputation, conduit failure,
reinfection, early mortality, and late mortality for studies involving extra-anatomic bypass treatment for infected aortic
grafts.Studies with zero events for an outcome are not shown in the Forrest plot. Relative weights are calculated among those studies with at least one event for a
specific outcome.
JOURNAL OF VASCULAR SURGERY
July 200645.e5 O’Connor et alAPPENDIX H (online only). Estimated mean event rates for the outcomes of amputation, conduit failure,
reinfection, early mortality, and late mortality for studies involving rifampicin-bonded prosthesis replacement treatment
for infected aortic grafts.
Studies with zero events for an outcome are not shown in the Forrest plot. Relative weights are calculated among those studies with at least one event for a
specific outcome.
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 1 O’Connor et al 45.e6APPENDIX I (online only). Estimated mean event rates for the outcomes of amputation, conduit failure, reinfection,
early mortality, and late mortality for studies involving cryopreserved allograft replacement treatment for infected aortic
grafts.Studies with zero events for an outcome are not shown in the Forrest plot. Relative weights are calculated among those studies with at least one event for a
specific outcome.
JOURNAL OF VASCULAR SURGERY
July 200645.e7 O’Connor et alAPPENDIX J (online only). Estimated mean event rates for the outcomes of amputation, conduit failure, reinfection,
early mortality, and late mortality for studies involving autogenous vein replacement treatment for infected aortic grafts.Studies with zero events for an outcome are not shown in the Forrest plot. Relative weights are calculated among those studies with at least one event for a
specific outcome.
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 1 O’Connor et al 45.e8APPENDIX K (online only). Standardized scoring system for studies.
Blinded review
Source of the
information
1. Was the paper published in a peer-reviewed journal or, if not, was the study
reviewed by some other group?
2. Is the purpose of the study presented in the publication applicable to the
meta-analysis to be performed?
3. If unpublished information from the investigator is required, are there
problems of recall or missing information?
4. Are the data provided complete enough for inclusion in this meta-analysis?
Score / 4
Study design 5. Is the design described?
6. Is the design appropriate to the study questions?
7. Are there clear inclusion and exclusion criteria?
8. Are the procedures for randomization (if applicable) and blinding de-
scribed?
9. Are experimental methods clearly defined?
Score / 5
Study outcomes 10. Are the outcomes clearly defined?
11. Are the methods of measurement clearly defined?
12. Do the outcome measures answer the study questions?
Score / 3
Study subjects 13. Did subjects meet the inclusion and exclusion criteria?
14. Are methods of diagnosis defined and reliable?
15. Are demographics for all subject groups included?
Score / 3
Controls 16. If there are parallel controls, are they comparable to the subjects?
17. If historical controls are used is the data of good quality and from known
sources?
Score / 2
Study implementation 18. Were inclusion and exclusion criteria strictly adhered to?
19. Are non-compliant or drop-out subjects accounted for?
20. In a multi-group study, were the groups comparable at baseline for prog-
nostic factors?
21. Have treatment methods, population demographics and/or reporting
methods changed significantly since the study was performed?
Score / 4
Treatment protocol 22. Were treatment regimens followed?
23. Were there any concomitant treatments?
24. Was there a high rate of drop-outs or non-compliant subjects?
Score / 3
Methods 25. Are the laboratory/surgical methods used in the study known to be accu-
rate and still considered valid today?
26. Are the surgical procedures that were used in the study still applicable?
Score / 2
Statistics 27. Are the analytical methods clearly described and appropriate for the data
and study design?
28. Are the conclusions of the study consistent with the descriptive and infer-
ential statistical results?
Score / 2TOTAL Score / 28
